文献速递外周动脉疾病

西洛他唑真实世界药物警戒研究:基于FAERS数据库的不比例分析

A Real-World Pharmacovigilance Study of Cilostazol Based on the Food and Drug Administration Adverse Event Reporting System: A Cross-Sectional Disproportionality Analysis.
PubMed 文献 · Ann Vasc Surg · 2026-02-17

本研究基于FAERS数据库2004至2024年数据,采用三种不比例分析方法检测西洛他唑相关不良事件信号。

要点

  • 西洛他唑相关不良事件主要涉及心脏疾病和检查类指标。
  • 检出11个药品说明书未列出的新信号,需关注临床监测。
  • 6个新信号属于重要医学事件,包括脑梗死、室颤、休克和DIC等。

核心结论

  • 西洛他唑真实世界不良事件信号涉及多个系统器官分类,存在11个未列于说明书的新信号,其中6个为重要医学事件。

研究设计与样本

  • 基于FAERS数据库2004至2024年的横断面不比例分析,共纳入513份以西洛他唑为主要怀疑药物的报告,涉及774个不良事件。

主要发现

  • 多数不良事件与心脏疾病和检查类指标相关。
  • 与药品说明书比对后,发现11个新信号,其中6个为重要医学事件:脑梗死、医疗装置血栓、室颤、腔隙性梗死、休克和弥散性血管内凝血。

关键数值与推荐

  • 信号检测采用报告比值比、英国药品和健康产品管理局综合标准及贝叶斯置信传播神经网络三种方法。
  • 513份报告中西洛他唑为主要怀疑药物,相关不良事件774个。
  • 11个信号未列于药品说明书,其中6个属于重要医学事件术语列表。

临床怎么用

  • 临床应关注西洛他唑相关心脏疾病和检查类指标异常,对脑梗死、室颤、休克、DIC等新信号保持警惕。
  • 建议在用药监测中结合真实世界信号,加强风险识别与临床监控。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cilostazol is used for the treatment of intermittent claudication, but long-term efficacy and safety data are predominantly derived from case reports or clinical trials, with a notable absence of large-scale, real-world comprehensive safety data. In this study, we applied data mining algorithms to identify adverse drug reaction signals associated with cilostazol that are not currently listed on its drug label, with the objective of enhancing drug safety. METHODS: From 2004 to 2024, adverse event (AE) reports associated with cilostazol were examined in the Food and Drug Administration Adverse Event Reporting System (FAERS) database. For signal detection, three disproportionality metrics were calculated: the reporting odds ratio, the United Kingdom Medicines and Healthcare Products Regulatory Agency omnibus standard, and Bayesian Confidence Propagation Neural Network. The identified signals were compared against the adverse drug reactionslisted on the drug label. RESULTS: A total of 513 reports identified cilostazol as the primary suspect, with 774 AEs associated with cilostazol. Twenty-eight AE signals were detected that met the data mining criteria for reporting odds ratio, United Kingdom Medicines and Healthcare Products Regulatory Agency omnibus standard, and Bayesian Confidence Propagation Neural Network. These signals belong to 10 different system organ classifications (SOCs). The majority of the AEs were related to cardiac disorders and investigations. The detected signals were compared against the drug label, revealing 11 new signals not previously listed. Of these, six were included in the important medical event (IME) terms list, namely cerebral infarction, thrombosis in medical devices, ventricular fibrillation (VF), lacunar infarction, shock, and disseminated intravascular coagulation (DIC). CONCLUSION: This study offers critical support for the clinical monitoring and risk identification of cilostazol-related AEs.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Zhang HY, Xiao L, Chen K, et al. A Real-World Pharmacovigilance Study of Cilostazol Based on the Food and Drug Administration Adverse Event Reporting System: A Cross-Sectional Disproportionality Analysis. Ann Vasc Surg. 2026. PMID: 41713801. doi:10.1016/j.avsg.2026.01.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。